MX2019009908A - Combinacion de un agonista de ppar con un agonista de fxr. - Google Patents

Combinacion de un agonista de ppar con un agonista de fxr.

Info

Publication number
MX2019009908A
MX2019009908A MX2019009908A MX2019009908A MX2019009908A MX 2019009908 A MX2019009908 A MX 2019009908A MX 2019009908 A MX2019009908 A MX 2019009908A MX 2019009908 A MX2019009908 A MX 2019009908A MX 2019009908 A MX2019009908 A MX 2019009908A
Authority
MX
Mexico
Prior art keywords
agonist
combination
ppar
fxr
fxr agonist
Prior art date
Application number
MX2019009908A
Other languages
English (en)
Inventor
Noel Benoît
Walczak Robert
Belanger Carole
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2019009908A publication Critical patent/MX2019009908A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación de principios activos para su uso en el tratamiento de enfermedades.
MX2019009908A 2017-02-21 2018-02-21 Combinacion de un agonista de ppar con un agonista de fxr. MX2019009908A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17157279 2017-02-21
EP17162161 2017-03-21
EP17165131 2017-04-05
PCT/EP2018/054305 WO2018153933A1 (en) 2017-02-21 2018-02-21 Combination of a ppar agonist with a fxr agonist

Publications (1)

Publication Number Publication Date
MX2019009908A true MX2019009908A (es) 2019-10-14

Family

ID=61223919

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009908A MX2019009908A (es) 2017-02-21 2018-02-21 Combinacion de un agonista de ppar con un agonista de fxr.

Country Status (15)

Country Link
US (1) US20200054589A1 (es)
EP (1) EP3585374B1 (es)
JP (1) JP2020508316A (es)
KR (1) KR20190117632A (es)
CN (1) CN110300580A (es)
AU (1) AU2018223146B2 (es)
BR (1) BR112019017312A2 (es)
CA (1) CA3051776A1 (es)
ES (1) ES2959842T3 (es)
IL (1) IL268426A (es)
MX (1) MX2019009908A (es)
PH (1) PH12019501905A1 (es)
SG (1) SG11201906987RA (es)
WO (1) WO2018153933A1 (es)
ZA (1) ZA201906100B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3130718A1 (en) * 2019-04-10 2020-10-15 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
WO2021231644A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN115811972A (zh) * 2020-05-13 2023-03-17 拓臻制药公司 肝脏病症的组合治疗
AU2021332217A1 (en) 2020-08-25 2023-05-11 Eli Lilly And Company Polymorphs of an ssao inhibitor
WO2022051321A1 (en) * 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
MX2023002799A (es) * 2020-09-11 2023-05-26 Terns Pharmaceuticals Inc Formulaciones de dispersión sólida de un agonista de fxr.
TW202317110A (zh) * 2021-07-06 2023-05-01 中國大陸商甘萊製藥有限公司 用於治療肝臟疾病的聯合治療
CN116848095B (zh) * 2021-08-13 2024-05-24 礼邦生物医药(江苏)有限公司 氘代化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT364688B (de) 1979-07-19 1981-11-10 Gergely Gerhard Verfahren zur herstellung eines aromaproduktes
CA2440680C (en) 2001-03-12 2010-06-01 Roberto Pellicciari Steroids as agonists for fxr
AU2003225903A1 (en) 2002-03-21 2003-10-08 Curagen Corporation Methods of using farnesoid x receptor (fxr) agonists
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
AU2003290796A1 (en) 2002-11-14 2004-06-15 The Scripps Research Institute Non-steroidal fxr agonists
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
EP1562915A1 (en) 2002-11-22 2005-08-17 SmithKline Beecham Corporation Farnesoid x receptor agonists
FR2857361B1 (fr) 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US7846960B2 (en) 2006-05-24 2010-12-07 Eli Lilly And Company FXR agonists
US8106077B2 (en) 2006-05-24 2012-01-31 Eli Lilly And Company Compounds and methods for modulating FXR
JP4970538B2 (ja) 2006-06-29 2012-07-11 エフ．ホフマン−ラ ロシュ アーゲー ベンゾイミダゾール誘導体、それらの製造方法、ｆｘｒアゴニストとしてのそれらの使用及びそれらを含む製剤
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
WO2008157270A1 (en) 2007-06-13 2008-12-24 Smithkline Beecham Corporation Farnesoid x receptor agonists
CN101877966A (zh) 2007-07-02 2010-11-03 葛兰素史密丝克莱恩有限责任公司 类法尼醇x受体激动剂
CA2697167C (en) 2007-08-27 2013-07-16 F. Hoffmann-La Roche Ag Benzimidazole derivatives used as fxr agonists
WO2009062874A2 (en) 2007-11-15 2009-05-22 F. Hoffmann-La Roche Ag Benzimidazole derivatives and their use as fxr agonists
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
BRPI0919248A2 (pt) 2008-09-25 2019-09-24 Hoffmann La Roche derivados de 3-amino-indazol ou 3-amino-4,5,6,7-tetraidroindazol
CN102164899B (zh) 2008-09-25 2014-11-26 霍夫曼-拉罗奇有限公司 用作抗异常脂肪血症及相关疾病的fxr调节剂的取代的吲唑或四氢吲唑类
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8309581B2 (en) 2009-09-29 2012-11-13 Hoffmann-La Roche Inc. Benzimidazole derivatives
WO2011144579A1 (en) 2010-05-17 2011-11-24 Genfit Improved preparation of chalcone derivatives
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
DK3360882T3 (da) 2013-05-14 2021-03-08 Intercept Pharmaceuticals Inc 11-hydroxyl-6-substituterede derivater af galsyre og aminosyrekonjugater deraf som farnesoid x receptormodulatorer
CA2942403A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Fxr agonists and methods for making and using
CN106999551A (zh) 2014-11-06 2017-08-01 英安塔制药有限公司 作为fxr/tgr5激动剂的胆汁酸类似物和其使用方法
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MX2017006833A (es) 2014-11-26 2018-02-13 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
EP3253382B1 (en) * 2015-02-06 2021-11-17 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
KR20170131644A (ko) * 2015-03-26 2017-11-29 티3디 테라퓨틱스, 인크. 인단 아세트산 유도체를 사용한 간 질환의 치료 방법

Also Published As

Publication number Publication date
ZA201906100B (en) 2023-08-30
KR20190117632A (ko) 2019-10-16
PH12019501905A1 (en) 2020-06-08
US20200054589A1 (en) 2020-02-20
EP3585374B1 (en) 2023-07-19
ES2959842T3 (es) 2024-02-28
CA3051776A1 (en) 2018-08-30
SG11201906987RA (en) 2019-09-27
AU2018223146B2 (en) 2023-12-21
EP3585374A1 (en) 2020-01-01
JP2020508316A (ja) 2020-03-19
WO2018153933A1 (en) 2018-08-30
BR112019017312A2 (pt) 2020-04-14
IL268426A (en) 2019-09-26
CN110300580A (zh) 2019-10-01
AU2018223146A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
ZA201906100B (en) Combination of a ppar agonist with a fxr agonist
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
PH12015502788A1 (en) Antibody formulations and methods
PH12017500933A1 (en) Sublingual administration of riluzole
MX2016013280A (es) Composiciones topicas para el alivio del dolor, manufactura y uso.
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
PH12017500934A1 (en) Sublingual formulation of riluzole
TN2016000535A1 (en) Ppar compounds for use in the treatment of fibrotic diseases.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
IL246855A0 (en) Materials for use in the treatment of retinitis
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
MX2017003020A (es) Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevencion de la acumulacion de grasa.
MX2020003768A (es) Composiciones acuosas herbicidas y metodos para usar las mismas.
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
MA40574A (fr) Traitement de maladies fibrotiques
EA201991866A1 (ru) Комбинированная терапия
PH12020500472A1 (en) Autotaxin inhibitor compounds
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis